Abstract

BackgroundThe fecal calprotectin (FC) level is widely used as a non-invasive method for identifying patients with active Crohn's disease (CD) and ulcerative colitis. Gastrointestinal involvement of Behçet's syndrome (GIBS) shows...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0339 Fecal calprotectin levels as an indicator of active disease in behÇet's syndrome patients with gastrointestinal involvement: a controlled study
H Yazici ... I Hatemi
Annals of the Rheumatic Diseases | VOL. 76
H Yazici, et. al.H Yazici ... I Hatemi
01 Jun 2017
COMPARING OF FAECAL CALPROTECTIN LEVELS IN PATIENTS WITH OSTEOARTHRITIS TAKING NSAID TREATMENT AND PATIENTS WITHOUT NSAIDS THERAPY
Andrii Kuzminets ... Artem Panin
EUREKA: Health Sciences | VOL. 2
Andrii Kuzminets, et. al.Andrii Kuzminets ... Artem Panin
31 Mar 2020
Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis.
Seniha Aktakka ... Tennur Atabay
Bosnian journal of basic medical sciences | VOL. 16
Seniha Aktakka, et. al.Seniha Aktakka ... Tennur Atabay
01 Jan 2015
Faecal calprotectin levels after rifaximin treatment in patients with irritable bowel syndrome with diarrhoea: A single-center prospective study
Hany Hussein ... Eslam Safwat
Arab Journal of Gastroenterology | VOL. 21
Hany Hussein, et. al.Hany Hussein ... Eslam Safwat
12 Sep 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers